NCI Study Targets Barriers to Colorectal Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

BETHESDA, Md—National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

Questionnaires are being sent to a representative sample that includes 1,389 primary care physicians, 1,042 medical specialists, and 323 health plan medical directors. Researchers are seeking data on factors that may affect the use of screening and diagnostic follow-up in community practices. The study aims to assess the knowledge of physicians and their attitudes, practice patterns, and health plan guidelines for providing or promoting colorectal cancer screening.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content